Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
DexCom reported its Q3 2022 financial results, with revenues increasing 18% year-over-year to $769.6 million. U.S. revenue grew 17% and international revenue soared 22%. GAAP operating income reached $147.5 million (19.2% of revenue), up from $118.3 million in Q3 2021. The company updated its annual revenue guidance to $2.88 - 2.91 billion. Significant strategic moves include launching the Dexcom G7 in five countries and expanding access to CGM through NHS inclusion.
DexCom, Inc. (NASDAQ: DXCM) has launched its inaugural program, Dexcom U, aimed at supporting college athletes with diabetes. The program features 14 athletes from 11 sports, promoting representation and inspiration for aspiring athletes facing similar challenges. A survey reveals that 43% of adults with Type 1 diabetes considered quitting sports due to their condition. Dexcom U, in collaboration with ESPN's Adam Schefter, provides mentorship and a platform for these athletes. The program emphasizes the role of continuous glucose monitoring in empowering athletes to manage their diabetes effectively.
Dexcom announces the launch of its G7 Continuous Glucose Monitoring (CGM) System in the UK, Ireland, Germany, Austria, and Hong Kong, aimed at people aged two and older. The G7 features the fastest sensor warmup in the market, with no finger sticks required, and builds on the accuracy of Dexcom's previous products. A global streaming launch event showcased the device, with plans for launches in New Zealand and South Africa soon. With improved design and integration into automated insulin delivery systems, Dexcom G7 marks a significant advancement in diabetes management.
DexCom, Inc. (NASDAQ:DXCM) will release its third quarter 2022 financial results on October 27, 2022, after market close.
A conference call is scheduled for 4:30 p.m. (Eastern Time) on the same day to review performance, with a webcast available on their investor relations website.
Investors can call in at (866) 374-5140 (US/Canada) or (404) 400-0571 (International) using confirmation number 56107665#.
DexCom, Inc. (NASDAQ:DXCM) announced that Jereme Sylvain, Executive Vice President and CFO, will present updates at upcoming investor conferences. The events include the Wells Fargo 2022 Healthcare Conference on September 7, 2022, at 2:35 PM (EST), and the Baird 2022 Global Healthcare Conference on September 14, 2022, at 8:30 AM (EST). Webcasts for these presentations will be available on the DexCom Investor Relations website, offering future access to the discussions.
DexCom, Inc. (NASDAQ: DXCM) has announced the promotion of Jake Leach to chief operating officer. Previously serving as chief technology officer, Leach has been instrumental in developing the company's continuous glucose monitoring (CGM) systems since 2004. The new role will see him take charge of product management and oversee operations, R&D, and quality control, reinforcing DexCom's commitment to innovation in diabetes technology. His expanded leadership aims to position DexCom for sustainable growth in providing CGM solutions to a wider audience.
DexCom, Inc. (NASDAQ:DXCM) announces that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 10:30 AM (EST). The presentation aims to provide an update on the company's ongoing efforts in diabetes care technology. Interested parties can access the webcast through the Dexcom Investor Relations website, where it will also be archived for future viewing.
The Dexcom ONE rt-CGM system has been officially listed on the NHS drug tariff in England, Wales, Scotland, and Northern Ireland, making it the first scan-free and finger prick-free device available for prescription for individuals with Type 1 and Type 2 diabetes who use insulin. This significant milestone, effective from August 1, enables easier access to advanced diabetes management technology. Dexcom aims to enhance patient outcomes and provide more choices in diabetes care through this initiative, in line with NICE's new guidelines on glucose sensors.
DexCom reported a 17% increase in Q2 2022 revenue, reaching $696.2 million, driven by strong customer growth and international expansion.
U.S. revenue grew 11%, while international revenue surged 39%. GAAP operating income fell to $77.0 million, down 590 basis points year-over-year, with a decline in non-GAAP operating income to $101.9 million.
Net income decreased to $50.9 million or $0.12 per diluted share. The company updated its fiscal 2022 guidance, projecting revenue between $2.86 billion and $2.91 billion, reflecting a growth rate of 17-19%.
Dexcom (NASDAQ: DXCM) enhances user experience by launching its G6 mobile app in Spanish, facilitating easier access for Spanish-speaking diabetes patients. This feature addresses language barriers that impact healthcare quality. As reported, diabetes affects 11.8% of U.S. Latino adults, with a significant risk for complications. The updated app is available on compatible iOS and Android devices, contributing to health equity and improved diabetes management. The company aims to empower users with real-time glucose monitoring, fostering better health decisions.
FAQ
What is the current stock price of DexCom (DXCM)?
What is the market cap of DexCom (DXCM)?
What does DexCom, Inc. specialize in?
When was DexCom, Inc. founded?
What are some of DexCom's key products?
How do DexCom's CGM systems benefit diabetic patients?
What recent achievements has DexCom made?
How is DexCom integrating its CGM systems with other technologies?
What is the significance of DexCom's strategic partnerships?
What is DexCom's approach to innovation?
How does DexCom support the community?
What financial trends are seen in DexCom's performance?
